X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AJANTA PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AJANTA PHARMA IPCA LABS/
AJANTA PHARMA
 
P/E (TTM) x 28.9 21.9 131.9% View Chart
P/BV x 3.4 5.2 66.6% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   AJANTA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
AJANTA PHARMA
Mar-18
IPCA LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,818 38.3%   
Low Rs4001,106 36.2%   
Sales per share (Unadj.) Rs260.2239.5 108.7%  
Earnings per share (Unadj.) Rs19.052.8 35.9%  
Cash flow per share (Unadj.) Rs33.159.5 55.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0230.0 92.6%  
Shares outstanding (eoy) m126.2088.77 142.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.16.1 34.5%   
Avg P/E ratio x28.927.7 104.2%  
P/CF ratio (eoy) x16.624.6 67.4%  
Price / Book Value ratio x2.66.4 40.4%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,120129,782 53.3%   
No. of employees `00013.36.8 195.1%   
Total wages/salary Rs m7,3593,765 195.5%   
Avg. sales/employee Rs Th2,477.43,128.4 79.2%   
Avg. wages/employee Rs Th555.2554.0 100.2%   
Avg. net profit/employee Rs Th180.6689.7 26.2%   
INCOME DATA
Net Sales Rs m32,83621,258 154.5%  
Other income Rs m418242 173.0%   
Total revenues Rs m33,25421,499 154.7%   
Gross profit Rs m4,5056,584 68.4%  
Depreciation Rs m1,777596 298.3%   
Interest Rs m2404 5,858.5%   
Profit before tax Rs m2,9056,226 46.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,539 33.2%   
Profit after tax Rs m2,3944,686 51.1%  
Gross profit margin %13.731.0 44.3%  
Effective tax rate %17.624.7 71.2%   
Net profit margin %7.322.0 33.1%  
BALANCE SHEET DATA
Current assets Rs m19,45512,236 159.0%   
Current liabilities Rs m10,0763,461 291.2%   
Net working cap to sales %28.641.3 69.2%  
Current ratio x1.93.5 54.6%  
Inventory Days Days9860 162.6%  
Debtors Days Days6784 79.2%  
Net fixed assets Rs m20,26011,140 181.9%   
Share capital Rs m252177 142.7%   
"Free" reserves Rs m26,63320,237 131.6%   
Net worth Rs m26,88620,414 131.7%   
Long term debt Rs m2,34010 23,169.3%   
Total assets Rs m41,17324,486 168.1%  
Interest coverage x13.11,519.4 0.9%   
Debt to equity ratio x0.10 17,591.9%  
Sales to assets ratio x0.80.9 91.9%   
Return on assets %6.419.2 33.4%  
Return on equity %8.923.0 38.8%  
Return on capital %10.830.5 35.3%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64211,667 134.1%   
Fx outflow Rs m4,8841,616 302.3%   
Net fx Rs m10,75910,052 107.0%   
CASH FLOW
From Operations Rs m3,4112,854 119.5%  
From Investments Rs m-1,354-2,604 52.0%  
From Financial Activity Rs m-1,304-2 65,205.0%  
Net Cashflow Rs m753248 303.6%  

Share Holding

Indian Promoters % 45.9 73.8 62.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 1.6 735.5%  
FIIs % 25.3 7.6 332.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.0 102.4%  
Shareholders   36,892 20,968 175.9%  
Pledged promoter(s) holding % 2.1 4.4 48.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 17, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - ALEMBIC PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS